At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 161–170 of 615 results.
-
Researchers are seeking the best dose of CLSP-1025 to use in people with advanced solid tumors. The people in this study have cancers with a mutation (change) in the p53 gene called R175H. They are also positive for a specific human leukocyte antigen (HLA type A*0201). HLA is a protein on cells that plays an important role in the immune response to foreign substances.
-
Acute lymphoblastic leukemia (ALL) in infants (babies under 1 year of age) can be challenging to treat. Researchers in this study are assessing the addition of 2 new drugs to standard chemotherapy for ALL in infants.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth
-
The purpose of this study is to assess the effectiveness of adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy for patients who have a recurrence of their prostate cancer after surgery (prostatectomy). Specifically, there must have been cancer originally found in the lymph nodes at the time of surgery for patients to be eligible for this study. The treatment being evaluated is a "salvage therapy" for recurrent prostate cancer. Patients will be randomly assigned to receive hormone therapy and radiation therapy after prostate cancer surgery with or without apalutamide, abiraterone acetate, and prednisone.
-
The purpose of this study is to assess the safety and effectiveness of giving the investigational immunotherapy drug INCMGA00012 in combination with gemcitabine and docetaxel in patients with inoperable or metastatic soft tissue sarcoma. Gemcitabine and docetaxel are standard treatments for this disease; researchers believe that adding INCMGA00012 may make treatment more effective.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers are assessing a new treatment for people with prostate cancer that has not spread but has a high risk of spreading. The new treatment, 2141-V11, will be given with standard prostate cancer therapies.
-
When vulvar cancer is removed, surgeons examine the first lymph nodes to which cancer might spread ("sentinel lymph nodes") to see if they contain cancer cells. If the sentinel lymph nodes contain cancer, the usual treatment is more surgery to remove all of the lymph nodes in the groin, followed by several weeks of radiation therapy to reduce the chance that the cancer will come back. However, removing all of the lymph nodes increases the risk of lymphedema, which causes uncomfortable swelling in the legs, as well as an elevated risk of infection.
-
Pirtobrutinib works by blocking a protein called BTK, which helps cancer cells grow and survive. By blocking this protein, pirtobrutinib may help stop cancer cells from growing and spreading. It is taken orally (by mouth).
-
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.